<DOC>
	<DOCNO>NCT00274846</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor peripheral blood stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell natural killer ( NK ) cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This clinical trial study well peripheral stem cell transplant use NK cell donor work treat patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Donor Peripheral Stem Cell Transplant Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate vivo expansion natural killer ( NK ) cell 14 day treatment allogeneic NK cell-enriched peripheral blood stem cell transplantation patient relapse acute myeloid leukemia . Secondary - Determine response rate , term complete remission , patient treat regimen . - Correlate complete remission rate NK cell expansion , interleukin-15 level , donor/recipient killer immunoglobulin receptor ( KIR ) ligand match status patient treat regimen . - Determine overall progression-free survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This open-label study . - Induction therapy : Patients receive fludarabine IV day -6 -2 cyclophosphamide IV day -5 day -5 -4 . - Allogeneic natural killer ( NK ) cell-enriched peripheral blood stem cell transplantation : Patients receive allogeneic NK cell-enriched peripheral blood stem cell IV 15-60 minute day 0 . Patients also receive interleukin-2 subcutaneously begin day 0 continue 3 time week 2 week . After completion study treatment , patient follow periodically 3 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) meet 1 follow criterion : Primary refractory disease ( complete response [ CR ] ≥ 2 induction therapy ) Relapsed disease CR ≥ 1 course standard reinduction therapy Secondary AML myelodysplastic syndrome Disease relapse ≥ 2 month transplant option donor lymphocyte infusion ( e.g. , recipient autologous umbilical cord blood transplant ) Chronic myelogenous leukemia myeloid blast crisis second chronic phase least one cycle standard chemotherapy imatinib Over 60 year age relapse within 6 month completion last chemotherapy Over 60 year age blast count &lt; 30 % within 10 day study entry Related HLAhaploidentical natural killer cell donor available No severe organ damage ( clinical laboratory assessment ) Performance status 50100 % No evidence active infection chest Xray No active fungal infection Active central nervous system ( CNS ) leukemia Pleural effusion large enough detectable chest xray Pregnant nursing ( positive pregnancy test ) Fertile patient must use effective contraception Less 60 day since prior transplant Less 3 day since prior prednisone Less 3 day since prior immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>